806MO - Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)

Interim results from a phase 1b study—presented during the ESMO Congress 2024—of patients with relapsed/refractory DLBCL treated with CAR T-cell therapy followed by 1 of the first 5 dose levels of NT-17 (efineptakin alfa) 21 days post–CAR T infusion showed that NT-I7 was safe and enhanced CAR-T factors associated with efficacy for standard-of-care CD19-directed CAR T-cell therapies. The objective response rate was 81.1% (complete response rate: 63.6%; partial response rate: 18.2%), and the progressive disease rate was 18.2%.